Literature DB >> 21062266

Dermatological findings in 61 mutation-positive individuals with cardiofaciocutaneous syndrome.

D H Siegel1, J McKenzie, I J Frieden, K A Rauen.   

Abstract

BACKGROUND: The RASopathies are a class of human genetic syndromes that are caused by germline mutations in genes which encode components of the Ras/mitogen-activated protein kinase (MAPK) pathway. Cardiofaciocutaneous (CFC) syndrome is characterized by distinctive craniofacial features, congenital heart defects, and abnormalities of the skin and hair.
OBJECTIVES: Systematically to characterize the spectrum of dermatological findings in mutation-positive individuals with CFC syndrome.
METHODS: Dermatological surveys were designed by the authors and distributed to the study participants through CFC International or directly by the authors (K.A.R. and D.H.S.) between July 2006 and August 2009. A second follow-up survey was collected between December 2007 and August 2009. When available, digital images and medical records of the participants were obtained. Study participants included individuals with CFC syndrome who have a mutation in BRAF, MAP2K1, MAP2K2 or KRAS.
RESULTS: Individuals with CFC syndrome have a variety of dermatological manifestations caused by dysregulation of the MAPK pathway in development. Numerous acquired melanocytic naevi were one of the most striking features: more than 50 naevi were reported by 23% (14/61) of participants and of those, more than 100 naevi were reported by 36% (5/14). Keratosis pilaris was reported in 80% (49/61) of cases. Ulerythema ophryogenes was common, occurring in 90% (55/61). Infantile haemangiomas occurred at a greater frequency, 26% (16/61), as compared with the general population.
CONCLUSIONS: CFC syndrome has a complex dermatological phenotype with many cutaneous features, some of which allow it to be differentiated from the other Ras/MAPK pathway syndromes. Multiple café-au-lait macules and papillomas were not identified in this CFC cohort, helping to distinguish CFC from other RASopathies such as neurofibromatosis type 1 and Costello syndrome.
© 2011 The Authors. BJD © 2011 British Association of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21062266      PMCID: PMC4063552          DOI: 10.1111/j.1365-2133.2010.10122.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  37 in total

1.  Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia.

Authors:  Siu T Yuen; Helen Davies; Tsun L Chan; Judy W Ho; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Wendy W Tsui; Annie S Chan; P Andrew Futreal; Michael R Stratton; Richard Wooster; Suet Y Leung
Journal:  Cancer Res       Date:  2002-11-15       Impact factor: 12.701

2.  GLUT1: a newly discovered immunohistochemical marker for juvenile hemangiomas.

Authors:  P E North; M Waner; A Mizeracki; M C Mihm
Journal:  Hum Pathol       Date:  2000-01       Impact factor: 3.466

3.  Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus.

Authors:  D Viskochil; A M Buchberg; G Xu; R M Cawthon; J Stevens; R K Wolff; M Culver; J C Carey; N G Copeland; N A Jenkins
Journal:  Cell       Date:  1990-07-13       Impact factor: 41.582

4.  Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome.

Authors:  M Tartaglia; E L Mehler; R Goldberg; G Zampino; H G Brunner; H Kremer; I van der Burgt; A H Crosby; A Ion; S Jeffery; K Kalidas; M A Patton; R S Kucherlapati; B D Gelb
Journal:  Nat Genet       Date:  2001-12       Impact factor: 38.330

Review 5.  ras oncogenes in human cancer: a review.

Authors:  J L Bos
Journal:  Cancer Res       Date:  1989-09-01       Impact factor: 12.701

6.  High frequency of BRAF mutations in nevi.

Authors:  Pamela M Pollock; Ursula L Harper; Katherine S Hansen; Laura M Yudt; Mitchell Stark; Christiane M Robbins; Tracy Y Moses; Galen Hostetter; Urs Wagner; John Kakareka; Ghadi Salem; Tom Pohida; Peter Heenan; Paul Duray; Olli Kallioniemi; Nicholas K Hayward; Jeffrey M Trent; Paul S Meltzer
Journal:  Nat Genet       Date:  2002-11-25       Impact factor: 38.330

7.  Capillary malformation-arteriovenous malformation, a new clinical and genetic disorder caused by RASA1 mutations.

Authors:  Iiro Eerola; Laurence M Boon; John B Mulliken; Patricia E Burrows; Anne Dompmartin; Shoji Watanabe; Romain Vanwijck; Miikka Vikkula
Journal:  Am J Hum Genet       Date:  2003-11-24       Impact factor: 11.025

8.  Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the PTPN11 gene.

Authors:  Maria Cristina Digilio; Emanuela Conti; Anna Sarkozy; Rita Mingarelli; Tania Dottorini; Bruno Marino; Antonio Pizzuti; Bruno Dallapiccola
Journal:  Am J Hum Genet       Date:  2002-06-07       Impact factor: 11.025

9.  GLUT1 immunoreaction patterns reliably distinguish hemangioblastoma from metastatic renal cell carcinoma.

Authors:  P E North; A Mizeracki; M C Mihm; R E Mrak
Journal:  Clin Neuropathol       Date:  2000 May-Jun       Impact factor: 1.368

10.  Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status.

Authors:  Harith Rajagopalan; Alberto Bardelli; Christoph Lengauer; Kenneth W Kinzler; Bert Vogelstein; Victor E Velculescu
Journal:  Nature       Date:  2002-08-29       Impact factor: 49.962

View more
  26 in total

1.  Cardio-facio-cutaneous syndrome: does genotype predict phenotype?

Authors:  Judith E Allanson; Göran Annerén; Yoki Aoki; Christine M Armour; Marie-Louise Bondeson; Helene Cave; Karen W Gripp; Bronwyn Kerr; Anna-Maja Nystrom; Katia Sol-Church; Alain Verloes; Martin Zenker
Journal:  Am J Med Genet C Semin Med Genet       Date:  2011-04-14       Impact factor: 3.908

Review 2.  Genetic Basis for Congenital Heart Disease: Revisited: A Scientific Statement From the American Heart Association.

Authors:  Mary Ella Pierpont; Martina Brueckner; Wendy K Chung; Vidu Garg; Ronald V Lacro; Amy L McGuire; Seema Mital; James R Priest; William T Pu; Amy Roberts; Stephanie M Ware; Bruce D Gelb; Mark W Russell
Journal:  Circulation       Date:  2018-11-20       Impact factor: 29.690

Review 3.  Cardio-facio-cutaneous syndrome: clinical features, diagnosis, and management guidelines.

Authors:  Mary Ella M Pierpont; Pilar L Magoulas; Saleh Adi; Maria Ines Kavamura; Giovanni Neri; Jacqueline Noonan; Elizabeth I Pierpont; Kent Reinker; Amy E Roberts; Suma Shankar; Joseph Sullivan; Melinda Wolford; Brenda Conger; Molly Santa Cruz; Katherine A Rauen
Journal:  Pediatrics       Date:  2014-09-01       Impact factor: 7.124

4.  Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study.

Authors:  Emily Y Chu; Karolyn A Wanat; Christopher J Miller; Ravi K Amaravadi; Leslie A Fecher; Marcia S Brose; Suzanne McGettigan; Lydia R Giles; Lynn M Schuchter; John T Seykora; Misha Rosenbach
Journal:  J Am Acad Dermatol       Date:  2012-05-18       Impact factor: 11.527

5.  Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.

Authors:  Sergey I Nikolaev; Donata Rimoldi; Christian Iseli; Armand Valsesia; Daniel Robyr; Corinne Gehrig; Keith Harshman; Michel Guipponi; Olesya Bukach; Vincent Zoete; Olivier Michielin; Katja Muehlethaler; Daniel Speiser; Jacques S Beckmann; Ioannis Xenarios; Thanos D Halazonetis; C Victor Jongeneel; Brian J Stevenson; Stylianos E Antonarakis
Journal:  Nat Genet       Date:  2011-12-25       Impact factor: 38.330

6.  A Novel SHOC2 Variant in Rasopathy.

Authors:  Vickie Hannig; Myoungkun Jeoung; Eun Ryoung Jang; John A Phillips; Emilia Galperin
Journal:  Hum Mutat       Date:  2014-09-11       Impact factor: 4.878

7.  Comparison of hair manifestations in cardio-facio-cutaneous and Costello syndromes highlights the influence of the RAS pathway on hair growth.

Authors:  J Urban; L Qi; H Zhao; I Rybak; K A Rauen; M Kiuru
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-01-02       Impact factor: 6.166

8.  Deletion of MAP2K2/MEK2: a novel mechanism for a RASopathy?

Authors:  M J M Nowaczyk; B A Thompson; S Zeesman; U Moog; P A Sanchez-Lara; P L Magoulas; R E Falk; J E Hoover-Fong; D A S Batista; S M Amudhavalli; S M White; G E Graham; K A Rauen
Journal:  Clin Genet       Date:  2013-04-02       Impact factor: 4.438

Review 9.  The RASopathies.

Authors:  Katherine A Rauen
Journal:  Annu Rev Genomics Hum Genet       Date:  2013-07-15       Impact factor: 8.929

10.  Negative regulation of Shh levels by Kras and Fgfr2 during hair follicle development.

Authors:  Anandaroop Mukhopadhyay; Suguna Rani Krishnaswami; Christopher Cowing-Zitron; Nai-Jung Hung; Heather Reilly-Rhoten; Julianne Burns; Benjamin D Yu
Journal:  Dev Biol       Date:  2012-11-01       Impact factor: 3.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.